| Fri, Apr 3, 2009 | | | Arzerra(tm) (ofatumumab) Granted Priority Review by FDA GlobeNewswire (Fri, Apr 3)
| | Wed, Mar 25, 2009 | | | Genmab A/S Summons Annual General Meeting GlobeNewswire (Wed, Mar 25)
| | Thu, Feb 26, 2009 | | | Arzerra(TM) (ofatumumab) MAA Accepted by EMEA GlobeNewswire (Thu, Feb 26)
| | Tue, Feb 24, 2009 | | | Genmab Announces Year End 2008 Financial Results GlobeNewswire (Tue, Feb 24)
| | Thu, Feb 5, 2009 | | | GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer GlobeNewswire (Thu, Feb 5)
| | Mon, Jan 5, 2009 | | | Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer GlobeNewswire (Mon, Jan 5)
| | Thu, Dec 18, 2008 | | | Genmab Sells Arzerra Co-Promotion Rights to GlaxoSmithKline GlobeNewswire (Thu, Dec 18)
| | Wed, Dec 10, 2008 | | | Genmab's Financial Calendar for 2009 GlobeNewswire (Wed, Dec 10)
| | Mon, Dec 8, 2008 | | | Genmab A/S: Arzerra(TM) (Ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukaemia (CLL) GlobeNewswire (Mon, Dec 8)
| Add GEN News to My Yahoo!:

| |
|